Surfactant therapy

Surfactant therapy is the medical administration of exogenous surfactant. Surfactants used in this manner are typically instilled directly into the trachea.[1]

Respiratory distress syndrome

Exogenous surfactant replacement therapy is effective in reducing RDS mortality and morbidity in preterm infants.[2][3][4][5]

Types of surfactants

Poractant alfa, Calfactant, Beractant are the types of natural surfactants commercially available in the United States. Although data is sometimes conflicting, it appears that there are no significant differences among the available preparations.

Adult respiratory distress syndrome

Surfactant therapy is not used to treat adults with adult respiratory distress syndrome because the evidence regarding its effect on patient-important outcomes is inconsistent.

See also

References

  1. ↑ Tarawneh A, Kaczmarek J, Bottino MN, Sant'anna GM. Severe airway obstruction during surfactant administration using a standardized protocol: a prospective, observational study. J Perinatol. 2012;32(4):270-5.
  2. ↑ Suresh GK, Soll RF. Overview of surfactant replacement trials. J Perinatol. 2005;25 Suppl 2:S40-4.
  3. ↑ Fujiwara T, Maeta H, Chida S, Morita T, Watabe Y, Abe T. Artificial surfactant therapy in hyaline-membrane disease. Lancet. 1980;1(8159):55-9.
  4. ↑ Liechty EA, Donovan E, Purohit D, et al. Reduction of neonatal mortality after multiple doses of bovine surfactant in low birth weight neonates with respiratory distress syndrome. Pediatrics. 1991;88(1):19-28.
  5. ↑ Kendig JW, Notter RH, Cox C, et al. Surfactant replacement therapy at birth: final analysis of a clinical trial and comparisons with similar trials. Pediatrics. 1988;82(5):756-62.
This article is issued from Wikipedia - version of the 6/30/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.